Acadian Asset Management LLC Takes Position in Shattuck Labs, Inc. (NASDAQ:STTK)

Acadian Asset Management LLC acquired a new stake in Shattuck Labs, Inc. (NASDAQ:STTK) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 44,193 shares of the company’s stock, valued at approximately $170,000. Acadian Asset Management LLC owned 0.09% of Shattuck Labs as of its most recent SEC filing.

Several other large investors have also bought and sold shares of STTK. Cannon Global Investment Management LLC bought a new position in shares of Shattuck Labs during the 1st quarter valued at about $91,000. Virtu Financial LLC bought a new stake in Shattuck Labs during the first quarter worth approximately $113,000. Susquehanna Fundamental Investments LLC bought a new stake in Shattuck Labs during the first quarter worth approximately $174,000. SG Americas Securities LLC grew its position in Shattuck Labs by 4.8% in the first quarter. SG Americas Securities LLC now owns 39,377 shares of the company’s stock worth $352,000 after buying an additional 1,788 shares during the last quarter. Finally, Rhumbline Advisers bought a new position in shares of Shattuck Labs in the second quarter valued at $182,000. Institutional investors own 58.74% of the company’s stock.

Insider Transactions at Shattuck Labs

In other Shattuck Labs news, CEO Taylor Schreiber acquired 14,400 shares of Shattuck Labs stock in a transaction that occurred on Wednesday, June 26th. The stock was acquired at an average price of $3.47 per share, with a total value of $49,968.00. Following the purchase, the chief executive officer now owns 34,502 shares in the company, valued at $119,721.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on STTK shares. BTIG Research lowered Shattuck Labs from a “buy” rating to a “neutral” rating in a research note on Monday, June 17th. Citigroup decreased their price target on Shattuck Labs from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, August 15th. HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of Shattuck Labs in a research note on Tuesday, August 27th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Shattuck Labs in a research note on Friday, August 2nd.

Shattuck Labs Stock Performance

Shares of STTK opened at $3.74 on Friday. The company has a market capitalization of $178.51 million, a PE ratio of -1.94 and a beta of 1.72. The company’s 50 day moving average price is $3.72 and its 200 day moving average price is $6.39. Shattuck Labs, Inc. has a 52 week low of $1.33 and a 52 week high of $11.76.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). Shattuck Labs had a negative net margin of 2,067.99% and a negative return on equity of 68.65%. The company had revenue of $1.61 million for the quarter, compared to analysts’ expectations of $0.50 million. The business’s quarterly revenue was up 704.5% on a year-over-year basis. On average, equities analysts forecast that Shattuck Labs, Inc. will post -1.72 earnings per share for the current fiscal year.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.